

Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas

Purhonen *et al.* (1) have refuted the data published in >50 reports (2, 3), neglecting to quote key articles or utilize relevant models, and have drawn unsubstantiated conclusions about the contribution of endothelial progenitor cells (EPCs) to tumor angiogenesis that are not supported by their non-quantitative data and superficially executed experiments. Their study (1) is flawed in experimental design and data interpretation. For example, they do not cite their own publication demonstrating the existence of VEGFR2⁺ EPCs (4) and neglect mentioning clinical validation (5, 6) and acknowledging mouse genetic models (2, 3), which provide convincing evidence for functional incorporation of EPCs into neovessels. Every figure lacks stereoconfocal-microscopic quantification of vessels that are presented as poorly defined longitudinal-linear streaks. Plasma VEGF-A levels were not measured *in vivo* in mice treated with VEGF-A, questioning their low level of VEGFR2⁺ EPC detection (3). Indeed, their FACS analysis is inaccurate because of (i) unconvincing CD31/VE-cadherin/VEGFR2 expression detected on MS-1 endothelium used as positive control and (ii) failure to show long-term marrow engraftment of donor-derived hematopoietic and authentic VEGFR2⁺LacZ⁺ colony-forming EPCs. APCmin mice develop only obstructive adenomas, rather than adenocarcinomas; therefore, it is an inappropriate model to study EPC incorporation, as Spring *et al.* (7) (not quoted) demonstrate that EPCs do not contribute to adenomas but contribute only to carcinomas/metastatic tumors. In the parabiotic model, wild-type EPCs compete with GPF⁺ EPCs, which underestimates EPC recruitment. Finally, study of 6-month-old VEGF-A-loaded Matrigel plugs in mice is impossible because Matrigel plugs are degraded within 2 months, particularly when VEGF-A by itself does not induce neoangiogenesis. No

quantification of patent vessels in Matrigel plugs was provided. This article fails to disprove the established role of EPCs in supporting neoangiogenesis in certain tumors (3, 5) and metastatic transition (2).

Robert S. Kerbel*, **Robert Benezra**[†], **David C. Lyden**[‡], **Koichi Hattori**[§], **Beate Heissig**[§], **Daniel J. Nolan**[¶], **Vivek Mittal**[¶], **Yuval Shaked**^{**}, **Sergio Dias**^{**}, **Francesco Bertolini**^{††}, and **Shahin Rafii**^{††§§}

*Sunnybrook Health Sciences Centre, Molecular and Cellular Biology Research, and Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; [†]Program of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY; [‡]Department of Pediatrics and ^{§§}Howard Hughes Medical Institute, Department of Genetic Medicine, Weill Medical College of Cornell University, New York, NY 10021; [§]Laboratory of Stem Cell Regulation, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo, Japan; [¶]Cancer Genome Research Center, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; ^{**}Angiogenesis Laboratory, CIPM, Portuguese Institute of Oncology, Lisbon, Portugal; and ^{††}Division of Hematology-Oncology, Department of Medicine, European Institute of Oncology, 20141 Milan, Italy

1. Purhonen S, *et al.* (2008) Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. *Proc Natl Acad Sci USA* 105:6620–6625.
2. Gao D, *et al.* (2008) Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. *Science* 319:195–198.
3. Bertolini F, Shaked Y, Mancuso P, Kerbel RS (2006) The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. *Nat Rev Cancer* 6:835–845.
4. Salven P, Mustjoki S, Alitalo R, Rafii S (2003) VEGFR-3 and CD133 identify a population of CD34⁺ lymphatic/vascular endothelial precursor cells. *Blood* 101:168–172.
5. Peters BA, *et al.* (2005) Contribution of bone marrow-derived endothelial cells to human tumor vasculature. *Nat Med* 11:261–262.
6. Minami E, Laflamme MA, Saffitz JE, Murry CE (2005) Extracardiac progenitor cells repopulate most major cell types in the transplanted human heart. *Circulation* 112:2951–2958.
7. Spring H, Schuler T, Arnold B, Hammerling GJ, Ganss R (2005) Chemokines direct endothelial progenitors into tumor neovessels. *Proc Natl Acad Sci USA* 102:18111–18116.

Author contributions: R.S.K., R.B., D.C.L., K.H., B.H., D.J.N., V.M., Y.S., S.D., F.B., and S.R. wrote the paper.

The authors declare no conflict of interest.

¶Present address: Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel.

§§To whom correspondence should be addressed at: Howard Hughes Medical Institute, Weill Medical College of Cornell University, 1300 York Avenue, Room A-863, New York, NY 10021. E-mail: srafi@med.cornell.edu.

© 2008 by The National Academy of Sciences of the USA